CRI Logo
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Types
    • Cancer Types
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Clinical Accelerator
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Ways to Give
    • Fundraise
    • Events
    • Partnership
    • Contact
Donate
  • Love in the Lab: Valentine’s Day with the Doctors Delgoffe

    CRI celebrates Valentine’s Day with immunologists Abby and Greg Delgoffe At first glance, one might not link…
    February 13, 2023| Max Mallet
  • 5 Things Patients, Caregivers, and Families Need to Know About Cancer

    Our CEO speaks with Medium/Authority Magazine about cancer, immunotherapy, and how she became CEO of the world’s…
    December 22, 2022| Max Mallet
  • Engineering Better CAR T Cells with CRI Lloyd J. Old STAR Yvonne Chen

    CRI STAR Yvonne Chen is exploring several strategies to improve the safety and effectiveness of CAR T…
    December 19, 2022| Max Mallet
  • Understanding and Overcoming Disparities in Cancer Treatment and Care

    Cancer not only affects each person differently, but it can also affect different communities overall in different…
    June 22, 2022| Max Mallet
  • Beyond the Prognosis and Treatment: Cancer Survivorship

    Cancer survivors have a diverse range of experiences with their diagnoses, treatment, and life after cancer.

    June 2, 2022| Max Mallet
  • Clinical Trials Drive Immunotherapy Progress. Are They for You?

    Immunotherapy clinical trials are critical endeavors that lead to breakthrough cancer treatments. 

    May 19, 2022| Max Mallet
  • How a Day of Golf and Beer Raised Money for Cancer Immunotherapy Research

    Birdies & Brews mixes beer and golf while raising funds for cancer immunotherapy research.

    May 6, 2022| Max Mallet
  • FDA Approves New LAG-3 Checkpoint Inhibitor Immunotherapy Combination

    Patients with unresectable or metastatic melanoma can now be treated with dual checkpoint blockade targeting the PD-1…

    March 24, 2022| Max Mallet

Cancer Research Institute
29 Broadway, Floor 4

New York, NY  10006-3111

Facebook Icon
X icon
YouTube icon
LinkedIn icon
Instagram icon
Threads icon
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Type
    • Cancer Type
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Clinical Accelerator
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Donate
    • Ways to Give
    • Fundraise
    • Events
    • Partnership
    • Contact

Uniting for a World Immune to Cancer

  • Accessibility Statement
  • Privacy Policy
  • Terms & Conditions
  • Site Map

*Immunotherapy results may vary from patient to patient.

©2025, Cancer Research Institute